The push toward decentralized clinical trials (DCTs) has transformed how sponsors collect data, engage patients, and monitor outcomes. Yet for software as a medical device (SaMD) embedded in these trials—think remote monitoring algorithms, digital biomarkers, or patient-facing diagnostics—the path to global approval remains anything but decentralized. SaMD in DCTs FDA vs EU MDR is not a simple either-or question; it is a dual challenge that requires aligning evidence expectations and security frameworks from the start. In 2026, as regulators on both sides of the Atlantic sharpen their focus on software validation, sponsors must treat regulatory strategy as a single, cohesive program rather than two separate submissions.
The Divergence That Keeps Sponsors Up at Night
At first glance, FDA and EU MDR seem to agree on fundamentals: SaMD must be clinically validated, risk-classified, and maintained under a robust quality system. But the practical requirements diverge sharply. The FDA evaluates SaMD through its software precertification framework and guidance on clinical decision support, leaning heavily on a risk-based, iterative approach. EU MDR, meanwhile, is anchored in the concept of intended purpose and demands a more prescriptive Technical Documentation file, including a rigorous Clinical Evaluation Report (CER). For a DCT using SaMD to monitor patient vitals or detect adverse events, the same algorithm can be scrutinized for different evidence thresholds depending on whether the trial is filed in Boston or Berlin.
This divergence becomes glaring when considering changes to software. The FDA allows a well-defined software lifecycle with continuous updates, while EU MDR requires that any significant change triggers a new conformity assessment. In a DCT where algorithms may be refined mid-trial based on incoming data, sponsors often find themselves planning two separate configuration management tracks. The result: duplicated workload, delayed timelines, and a diluted evidence base that satisfies neither regulator fully.
Building One Evidence Strategy That Speaks Two Languages
To bridge the FDA-EU MDR divide, sponsors need to design their evidence generation with both regulators in mind from the very first protocol draft. The key is not to generate twice but to generate smarter—creating a unified evidence package that addresses each regulator’s core concern without redundant studies.
Start with the Intended Purpose and Clinical Claim
Both FDA and EU MDR require a precise statement of what the SaMD does and what benefit it claims. In a DCT, this claim must be bracketed by the context of use: the patient population, the condition, the healthcare setting, and the level of health care professional involvement. Drafting this statement in a way that is simultaneously acceptable to both regulators—using language that is broad enough to cover remote use but explicit enough to satisfy MDR’s need for clinical evidence—is the foundation. From there, the clinical evaluation can be built as a modular dossier: one set of literature reviews, one set of clinical data, but with distinct analysis and presentation for each regulator.
Leverage Decentralized Data Streams as Real-World Evidence
In 2026, the biggest opportunity for alignment lies in the data that DCTs naturally generate. Sensor data, patient-reported outcomes, and passive monitoring provide an richness that traditional trials never offered. FDA has become increasingly receptive to real-world evidence (RWE) for SaMD, especially when used to supplement premarket clinical studies. EU MDR also allows RWE, but with stricter demands for data quality, traceability, and ethical approval. By designing the DCT’s data collection infrastructure to meet the higher EU standards, sponsors can produce evidence that satisfies the FDA’s curiosity while remaining fully compliant with MDR. This means documenting data provenance, ensuring device interoperability, and capturing adverse events in real time—practices that strengthen both submissions.
Plan for Adaptive Design and Changing Software
One of the most overlooked elements is how software versions are handled during the trial. A SaMD that is updated mid-trial to improve a machine learning model creates a moving target for regulators. The smart approach is to define a validation binding—a fixed version of the algorithm that remains locked for all primary endpoint analyses. Both FDA and MDR accept this if the change management process documents the impact on safety and performance. Instead of fighting the regulators’ differing expectations, sponsors can adopt a pre-specified montoring plan that demonstrates how each software iteration is validated against the same baseline evidence, thereby creating a clear thread from initial design to final post-market phase.
Security and Privacy: The Missing Pillar in Regulatory Alignment
Regulatory approval is no longer just about clinical performance. Cybersecurity is now a de facto pillar of medical device software, and it is where many FDA-EU MDR harmonization efforts fall apart. The FDA has issued cybersecurity guidance for premarket submissions, requiring a threat model, robust risk controls, and a software bill of materials (SBOM). EU MDR’s security requirements are less direct but embedded through the General Safety and Performance Requirements, particularly around protection against unauthorized access and data corruption. When SaMD operates in a DCT—outside hospital firewalls, on personal devices, across public networks—the security risk scopes expand significantly.
Define a Shared Security Architecture Early
Instead of treating cybersecurity as a post-hoc justification, sponsors should build a single security model that satisfies the most stringent of the two frameworks, then map it to the FDA and MDR. This model must cover the entire data chain: from the sensor to the patient’s phone, to the cloud, and finally to the trial database. Key elements include end-to-end encryption, multi-factor authentication for all users, continuous security monitoring, and a secure software update mechanism. By adopting the EU’s more explicit data protection expectations (under GDPR and the upcoming European Health Data Space), sponsors can voluntarily raise the bar for their FDA submission, which increasingly rewards proactive security practices.
Bring cybersecurity evidence into the clinical evaluation
Another fresh angle for 2026 is the integration of security evidence into the clinical evaluation itself. Regulators are beginning to understand that a security breach can directly impact clinical outcomes—if a bad actor tampers with a patient’s monitoring data, the trial results become meaningless. Sponsors who proactively include a cybersecurity validation report alongside their clinical performance data will be seen as pioneers. For EU MDR, this can be housed as part of the risk management file, while for FDA, it feeds into the premarket cybersecurity submission. Making this connection explicit helps both regulators see the SaMD as a closed-loop system: secure, effective, and trustworthy.
Practical Steps to Harmonize Your Regulatory Approach Right Now
Given the landscape in 2026, there are concrete actions every sponsor can take to align evidence and security for global approval without doubling effort.
- Create a cross functional regulatory team with members fluent in both FDA and EU MDR requirements. Do not rely on separate consultants who never speak. Weekly alignment sessions from protocol concept to submission are non-negotiable.
- Adopt a standards-based approach. Use shared technical standards like IEC 62304 for software lifecycle and IEC 81001-5-1 for security. These are recognized by both the FDA and the EU, making them the natural backbone for your documentation.
- Build a single technical documentation cloud environment. Structure your content so that the same underlying data can be rendered into an FDA-style premarket report or an MDR-style Technical Documentation file without rewriting the core.
- Engage with both regulators early. In 2026, there is no excuse for submitting without prior feedback. FDA provides Q-Submissions; EU offers MDR expert panels and guidance questions. Use these to clarify your SaMD’s classification and evidence expectations before running the full DCT.
- Run a security-by-design sprint during the clinical validation phase. Instead of leaving security testing to the end, perform continuous threat modeling and penetration testing in parallel with your clinical study. This will generate security evidence that can be incorporated into the clinical evaluation with minimal extra cost.
The Future of SaMD Approval Is Cohesive, Not Parallel
The days of treating FDA and EU MDR as two separate journeys are ending. For SaMD in DCTs, the most efficient path to global approval is a single, harmonized strategy where each piece of evidence serves multiple masters. By unifying the clinical evidence base and making security a first-class citizen, sponsors can reduce redundancy, avoid costly delays, and bring safe, effective digital tools to patients faster. In 2026, the winning regulatory strategy is not about filing twice—it’s about building once, with the foresight to satisfy both sides of the Atlantic seamlessly.
As decentralized clinical trials become the default for many therapeutic areas, the ability to align regulatory expectations will separate market leaders from laggards. It’s time to stop thinking in terms of “FDA vs EU MDR” and start thinking about what regulatory excellence looks like in a connected, software-enabled trial ecosystem.
